Avalo Therapeutics Director Makes Significant Stock Sale!

New insider activity at Avalo Therapeutics ( (AVTX) ) has taken place on November 17, 2025.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Director Jonathan Goldman recently sold 11,367 shares of Avalo Therapeutics stock, amounting to a total transaction value of $162,876. Recent Updates on AVTX stock Avalo Therapeutics has recently completed patient enrollment for its Phase 2 LOTUS trial of AVTX-009, aimed at treating hidradenitis suppurativa, exceeding its target with approximately 250 patients enrolled. This milestone reflects strong engagement from both investigators and patients, bringing the company closer to potentially offering a new treatment option for this chronic condition. Despite reporting a net loss of $30.6 million for the quarter ending September 30, 2025, Avalo maintains a strong cash position to support its operations for the next twelve months. The company’s financial performance has impacted its stock score negatively, reflecting operational and profitability challenges. However, the completion of the trial enrollment and the potential of AVTX-009 to address unmet medical needs could positively influence Avalo’s market position and investor confidence, with topline data expected in mid-2026. Spark’s Take on AVTX Stock According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral. The overall stock score is primarily influenced by significant financial challenges, including declining revenues and persistent losses. While technical indicators show some positive momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation. The absence of earnings call data and corporate events means these factors do not contribute to the score. To see Spark’s full report on AVTX stock, click here. More about Avalo Therapeutics YTD Price Performance: 79.24% Average Trading Volume: 355,235 Technical Sentiment Signal: Sell Current Market Cap: $274M